istock-956478432_patricia-dallaire

Patricia-Dallaire / iStockphoto.com

4 October 2018Americas

The problems with patenting antibodies

“When it comes to protecting biopharmaceutical inventions, particularly antibody inventions, there is definitely not a one-size-fits-all approach,” remarks Kathy Coulter, senior IP counsel at Bristol-Myers Squibb (BMS) in San Francisco.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York